Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis (Regulate-RA)

Overview

About this study

The purpose of this study is to evaluate and characterize the safety and tolerability of SBT777101, inclusing incidence, nature, and severity of adverse events, incidence and nature of dose-limiting toxicities (DLTs), and change from baseline in targeted vital signs, clinical laboratory tests and ECG parameters.
 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Body mass index (BMI) <35 kg/m^2, inclusive
  • Adult-onset, moderate-to-severe rheumatoid arthritis (RA)
  • Moderate-to-severe active disease
  • Clinical and/or ultrasound evidence of synovitis
  • Prior inadequate response to or unable to tolerate available RA therapies
  • Stable doses of RA medications for at least 30 days
  • Use of highly effective methods of contraception

Exclusion Criteria:

  • Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
  • Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
  • Recurrent infections or active infection
  • Active or untreated latent tuberculosis
  • Primary or secondary immunodeficiency
  • History of or current inflammatory joint disease other than RA

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/24/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Fawad Aslam, M.B.B.S., M.S.

Open for enrollment

Contact information:

Megan Hall M.S.N., R.N.

(480) 301-6373

Hall.Megan@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20562516

Mayo Clinic Footer